GSK: GSK Plc
About
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Current Value
$33.831 Year Return
Current Value
$33.831 Year Return
Key Details
Market Cap
$68.73B
P/E Ratio
21.68
1Y Stock Return
-4.26%
1Y Revenue Growth
9.06%
Dividend Yield
3.87%
Price to Book
3.7
Strategies that include GSK
Stock's related to GSK
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NVS | 40.17% | $203.18B | +6.96% | 3.57% |
| JNJ | 37.32% | $374.38B | +3.10% | 2.36% |
| EHC | 36.96% | $10.01B | +50.47% | 0.62% |
| AZN | 33.78% | $199.24B | +1.02% | 2.26% |
| WM | 33.67% | $88.91B | +28.97% | 1.33% |
| QGEN | 32.80% | $9.39B | +1.01% | 0.00% |
| MO | 32.78% | $94.96B | +36.03% | 7.02% |
| SNY | 32.47% | $120.29B | +3.27% | 4.24% |
| MMC | 32.10% | $110.22B | +12.11% | 1.35% |
| ABBV | 31.78% | $303.47B | +24.02% | 3.56% |
| WCN | 31.50% | $48.78B | +41.79% | 0.62% |
| SNN | 31.36% | $10.92B | -2.49% | 2.97% |
| CL | 31.29% | $77.00B | +21.96% | 2.09% |
| RPRX | 29.76% | $11.73B | -2.87% | 3.17% |
| SYK | 29.60% | $148.73B | +32.68% | 0.82% |
| HLN | 29.14% | $43.23B | +14.51% | 1.63% |
| DOX | 29.10% | $9.73B | +1.76% | 2.20% |
| SGRY | 28.65% | $2.97B | -28.90% | 0.00% |
| SAIC | 28.17% | $6.18B | +7.29% | 1.18% |
| CP | 27.97% | $70.18B | +5.92% | 0.74% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NTIC | -<0.01% | $134.44M | +28.17% | 1.97% |
| TBRG | 0.01% | $238.95M | +45.55% | 0.00% |
| SMC | 0.01% | $383.35M | +91.49% | 0.00% |
| ARCH | 0.01% | $3.16B | +10.27% | 1.21% |
| YOU | -0.02% | $2.46B | +32.30% | 1.11% |
| HLIT | -0.03% | $1.44B | +12.84% | 0.00% |
| LOMA | -0.03% | $1.24B | +62.91% | 0.00% |
| TCPC | 0.04% | - | - | 14.96% |
| AG | -0.06% | $1.94B | +18.38% | 0.28% |
| PEGA | -0.07% | $7.67B | +71.65% | 0.13% |
| EH | -0.10% | $584.66M | -15.89% | 0.00% |
| YY | -0.12% | $1.47B | -12.25% | 0.00% |
| HEAR | -0.12% | $303.60M | +45.24% | 0.00% |
| CODX | -0.13% | $33.85M | -15.87% | 0.00% |
| CRNC | -0.13% | $243.72M | -65.58% | 0.00% |
| VVV | -0.13% | $4.97B | +10.49% | 0.00% |
| GCI | -0.14% | $759.17M | +153.69% | 0.00% |
| FG | -0.15% | $5.94B | +11.80% | 1.76% |
| RRR | 0.15% | $2.98B | +12.13% | 1.99% |
| IREN | 0.16% | $1.83B | +207.59% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GPCR | -22.44% | $1.72B | -41.41% | 0.00% |
| HUSA | -22.03% | $18.58M | -19.77% | 0.00% |
| NINE | -19.59% | $53.38M | -37.31% | 0.00% |
| COHR | -16.48% | $16.35B | +193.50% | 0.00% |
| GEO | -12.46% | $4.02B | +193.76% | 0.00% |
| VSTA | -12.31% | $203.32M | -37.79% | 0.00% |
| CLLS | -11.72% | $134.09M | -34.04% | 0.00% |
| GERN | -11.66% | $2.43B | +106.15% | 0.00% |
| CANG | -11.48% | $282.47M | +245.13% | 0.00% |
| BVN | -11.47% | $3.12B | +34.06% | 0.00% |
| CCAP | -11.16% | - | - | 8.72% |
| BTCT | -10.89% | $58.86M | +395.83% | 0.00% |
| WMG | -10.62% | $16.15B | -6.65% | 2.23% |
| DUOL | -10.39% | $15.03B | +56.29% | 0.00% |
| LQDA | -10.35% | $859.06M | +51.04% | 0.00% |
| PJT | -10.21% | $3.81B | +88.02% | 0.62% |
| KOS | -9.92% | $1.89B | -41.00% | 0.00% |
| IHRT | -9.61% | $360.33M | -9.93% | 0.00% |
| DAKT | -9.24% | $668.95M | +20.40% | 0.00% |
| UNF | -9.16% | $3.51B | +14.43% | 0.67% |
ETF's related to GSK
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PPH | 55.53% | $606.64M | 0.36% |
| IXJ | 49.02% | $3.88B | 0.41% |
| XLV | 44.75% | $38.54B | 0.09% |
| IYH | 44.72% | $3.20B | 0.39% |
| VHT | 42.66% | $17.20B | 0.1% |
| FHLC | 41.43% | $2.75B | 0.084% |
| KXI | 39.87% | $697.87M | 0.41% |
| IHE | 39.40% | $596.24M | 0.39% |
| EWU | 39.07% | $3.15B | 0.5% |
| SCHY | 39.06% | $771.19M | 0.14% |
| RSPH | 38.81% | $879.32M | 0.4% |
| EFAV | 38.28% | $5.84B | 0.22% |
| ACWV | 37.66% | $4.26B | 0.2% |
| FXH | 37.09% | $1.16B | 0.62% |
| FLGB | 36.71% | $652.94M | 0.09% |
| USMV | 35.83% | $23.75B | 0.15% |
| EWL | 35.53% | $1.16B | 0.5% |
| IYK | 35.44% | $1.31B | 0.4% |
| XLP | 35.42% | $16.04B | 0.09% |
| FSTA | 34.77% | $1.20B | 0.084% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SILJ | -0.05% | $990.19M | 0.69% |
| EPU | -0.08% | $78.43M | 0.59% |
| FTXL | -0.17% | $1.32B | 0.6% |
| UNG | -0.21% | $928.64M | 1.06% |
| SOXQ | -0.40% | $478.59M | 0.19% |
| KMLM | -0.52% | $348.59M | 0.9% |
| YEAR | 0.62% | $1.14B | 0.25% |
| SOYB | -0.62% | $27.32M | 0.22% |
| SMH | -0.67% | $23.60B | 0.35% |
| PIN | 0.69% | $249.88M | 0.78% |
| COPX | -0.74% | $2.56B | 0.65% |
| SLVP | -0.79% | $235.94M | 0.39% |
| SIL | -0.82% | $1.28B | 0.65% |
| FEPI | -0.82% | $424.42M | 0.65% |
| PSI | 0.90% | $699.34M | 0.56% |
| PFFR | -0.92% | $110.83M | 0.45% |
| GDXJ | -1.04% | $5.12B | 0.52% |
| ICLO | -1.05% | $231.44M | 0.2% |
| IGBH | -1.05% | $93.80M | 0.14% |
| BLCN | -1.05% | $71.42M | 0.68% |
News
SeekingAlpha
Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.
Yahoo
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in adults with cholestatic pruritus (relentless itch) associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease. GLISTEN met its primary endpoint, with linerixibat improving itch, as demonstrated by a statistically significant reduction from baseline in monthly itch score over 24 weeks versus placebo. Also Read: GSK Raises Prospects For Withdrawn Blood
SeekingAlpha
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.
Yahoo
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D ProgramTORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ: MDCX TSXV: MDCX) (the “Company”) is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. “We are thrilled to welcome Dr. Mehmud to our leadership team,” stated Dr. Raza Bokhari, Exec. Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base
Yahoo
President-elect Donald Trump has selected Robert F. Kennedy Jr. for the position of Secretary of Health & Human Services (HHS). The appointment has drawn significant attention due to Kennedy Jr.'s controversial stance on vaccines, including his designation as one of the "Disinformation Dozen" during the COVID-19 pandemic. Following the announcement, vaccine-related stocks experienced a notable decline. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the implications of this appointment and shares reactions from market analysts regarding its potential impact on the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith
Yahoo
Electric vehicle stocks Tesla (TSLA) and Rivian (RIVN) are in focus amid reports that President-elect Donald Trump plans to end the federal tax credit for electric vehicle purchases. The $7500 subsidy has been a key incentive driving consumer adoption of EVs in the US, and its removal could make these vehicles less affordable. Additionally, vaccine maker stocks like Moderna (MRNA) and Pfizer (PFE) are falling after Trump named Robert F. Kennedy Jr. as Secretary of Health and Human Services. Kennedy Jr. has been openly skeptical of vaccines. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.